In a recent study, a pair of proteins identified women who went on to deliver preterm with specificity and sensitivity of 78 and 80 percent, respectively.
While SomaScan is the company's main source of revenue, it continues to develop its Dx business and will launch its first test in the second half of 2016.
Researchers from Protagen, Targos, and elsewhere have identified autoantibody biomarkers specific to patients diagnosed with prostate cancer.
Based on the Global Proteome Machine Database, the tool helps with identification of genomic variants that affect protein post-translational modification sites.
The Swedish firm, a spinout of Lund University, will evaluate the array-based blood tests to confirm, rule out, and monitor the autoimmune disease.
In Science this week: Neanderthal-derived DNA linked to modern ailments, and more.
Japan needs to catch up on its gene-editing research efforts, the Japan News writes.
Hundreds of people have signed an online petition calling for zero tolerance to sexual harassment in the sciences.
Jeff Huber, former Google X senior vice president, joins Grail as its CEO.